Skip to main content
  • Investors
  • Mediaopen in a new window
  • Contact Usopen in a new window
  • |
Ironwood Logoopen in a new window
  • Company
  • Science & Medicine
  • Patients
  • Responsibility
  • Careers
  • IR Home
  • Why Invest
  • Events & Presentations
  • Corporate Governance
    • Governance Documents
    • Executive Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financials
    • Quarterly Results
    • Annual Reports
    • SEC Filings
  • Investor FAQs
  • Press Releases
  • Investor Contacts
    • Investor Emails Alerts
    • RSS Feeds
  • IR Home
  • Why Invest
  • Events & Presentations
  • Corporate Governance
    • Governance Documents
    • Executive Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financials
    • Quarterly Results
    • Annual Reports
    • SEC Filings
  • Investor FAQs
  • Press Releases
  • Investor Contacts
    • Investor Emails Alerts
    • RSS Feeds
Close
Close
  • Investors
  • Company
  • Product
  • Research & Development
  • Patients
  • Partnerships
  • Careers
Close

Press Releases

Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
December 3, 2020
Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors
November 6, 2020
Ironwood Pharmaceuticals to Present at the 29th Annual Credit Suisse Healthcare Conference
November 5, 2020
Ironwood Pharmaceuticals Reports Strong Third Quarter 2020 Results and Increases Full Year 2020 Financial Guidance
November 5, 2020
Ironwood Pharmaceuticals Appoints Alexander Denner, Ph.D., to Board of Directors
October 22, 2020
Ironwood Pharmaceuticals to Host Third Quarter 2020 Investor Update Call
September 29, 2020
Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment
September 2, 2020
Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences
August 6, 2020
Ironwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million
July 23, 2020
Ironwood Pharmaceuticals to Host Second Quarter 2020 Investor Update Call
July 21, 2020
Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease (GERD)
May 27, 2020
Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with Irritable Bowel Syndrome with Diarrhea (IBS-D)
May 6, 2020
Ironwood Pharmaceuticals Reports First Quarter 2020 Results and Provides Update on Impact of COVID-19 Pandemic
April 28, 2020
Ironwood and Allergan Receive Notices of Allowance for Patent Applications Covering 72 mcg Dose of LINZESS® (linaclotide)
April 16, 2020
Ironwood Pharmaceuticals to Host First Quarter 2020 Investor Update Call
March 26, 2020
Ironwood Pharmaceuticals Provides Update on Impact of COVID-19
March 14, 2020
A message to our healthcare providers, patients and other partners during COVID-19
Download PDF format download (opens in new window)
February 26, 2020
Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology
February 25, 2020
Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences
February 19, 2020
Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
February 13, 2020
Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance
January 30, 2020
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2019 Investor Update Call
January 22, 2020
Ironwood and Allergan Announce Settlement with Teva Resolving LINZESS® (linaclotide) Patent Litigation
January 6, 2020
Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation
January 2, 2020
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

Investor Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Ironwood Pharmaceuticals, Inc., we strive to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Ironwood Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.

* Required

*
*





Email Alert Sign Up Confirmation

Ironwood Logoopen in a new window
  • Investors
  • Media
  • Contact us
Follow us on Linkedin Follow us on Twitter

COMPANY

  • Company Overview
  • Leadership
  • Open Payments & Transparecy

PRODUCT

  • Linzees

RESEARCH & DEVELOPMENT

  • Pipeline
  • Medical Affairs

PARTNERSHIPS

  • Overview
  • Grants

PATIENTS

  • Overview

RESPONSBILITY

  • Overview
  • Community Giving
  • Equity,Diversity & Inclusion
  • Sustainability
  • Safety & Compliance
  • Patients & Research

CAREERS

  • Working at Ironwood
  • Open Positions
  • Internships, Co-ops & Fellowships

INVESTORS

  • Home
  • Why Invest
  • Events & Presentations
  • Corporate Governance
  • Finanical Information
  • Investor FAQ
  • Press Releases
  • Investor Contacts
  • Copyright © Ironwood. All rights reserved Powered By Q4 Inc. 5.77.0.2 (opens in new window)
  • Privacy Policy
  • California Privacy Policy
  • Site Map
  • Terms of Use